Prognostic relevance of pS2 status in association with steroid receptor status and proliferative activity in node-negative breast cancer
- PMID: 1515241
- DOI: 10.1016/0959-8049(92)90507-x
Prognostic relevance of pS2 status in association with steroid receptor status and proliferative activity in node-negative breast cancer
Abstract
Expression of the oestrogen-regulated pS2 protein was investigated on paraffin-embedded sections of primary breast tumours from 200 node-negative patients. Immunoreactivity was observed in 56% of the cases. pS2 expression was inversely correlated with tumour size and proliferative activity, whereas a direct correlation was observed with steroid receptor. 5-year relapse free survival was influenced by tumour size (P = 0.02), oestrogen receptor status (P less than 0.05), and proliferative activity (P less than 0.01). No difference in relapse-free survival was observed between patients subdivided according to pS2 expression alone. However, among patients with oestrogen-receptor-negative tumors, pS2 expression predicted a shorter relapse-free survival.
Similar articles
-
Prediction of relapse and survival in breast cancer patients by pS2 protein status.Cancer Res. 1990 Jul 1;50(13):3832-7. Cancer Res. 1990. PMID: 2354435
-
Steroid receptors, pS2 and cathepsin D in early clinically node-negative breast cancer.Eur J Cancer. 1994;30A(1):5-11. doi: 10.1016/s0959-8049(05)80008-5. Eur J Cancer. 1994. PMID: 8142164
-
Immunoradiometric detection of pS2 and total cathepsin D in primary breast cancer biopsies: their correlation with steroid receptors.Br J Cancer. 1994 Mar;69(3):550-4. doi: 10.1038/bjc.1994.100. Br J Cancer. 1994. PMID: 8123486 Free PMC article.
-
Correlation between pS2 protein positivity, steroid receptor status and other prognostic factors in breast cancer.Int J Biol Markers. 1995 Apr-Jun;10(2):87-93. doi: 10.1177/172460089501000204. Int J Biol Markers. 1995. PMID: 7561244 Review.
-
Clinical significance of the estrogen regulated pS2 protein in mammary tumors.Crit Rev Oncol Hematol. 1993 Aug;15(1):13-21. doi: 10.1016/1040-8428(93)90017-x. Crit Rev Oncol Hematol. 1993. PMID: 8240704 Review.
Cited by
-
Association of pS2 (TFF1) release with breast tumour proliferative rate: in vitro and in vivo studies.Cell Prolif. 1999 Apr-Jun;32(2-3):107-18. doi: 10.1046/j.1365-2184.1999.32230107.x. Cell Prolif. 1999. PMID: 10535357 Free PMC article.
-
Immunohistochemical determination of pS2 in invasive breast carcinomas: a study on 942 cases.Breast Cancer Res Treat. 1995 May;34(2):119-28. doi: 10.1007/BF00665784. Breast Cancer Res Treat. 1995. PMID: 7647329 Clinical Trial.
-
Relationship of PS2 with response to tamoxifen therapy in patients with recurrent breast cancer.Br J Cancer. 1994 Dec;70(6):1217-23. doi: 10.1038/bjc.1994.476. Br J Cancer. 1994. PMID: 7981080 Free PMC article.
-
A second trefoil protein, ITF/hP1.B, is transcribed in human breast cancer.Breast Cancer Res Treat. 1996;38(2):145-51. doi: 10.1007/BF01806668. Breast Cancer Res Treat. 1996. PMID: 8861832
-
Trefoil peptides.Gut. 1999 Jun;44(6):890-5. doi: 10.1136/gut.44.6.890. Gut. 1999. PMID: 10323896 Free PMC article. Review. No abstract available.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical